news:: Press Releases
Back to Press Releases

Brain Science Institute Announces License Agreement to Develop Treatments for Neurological Disease

Johns Hopkins University's newly formed Brain Science Institute's NeuroTranslational Program has entered into a licensing agreement with pharmaceutical company Eisai Inc. to discover and develop small molecule glutamate carboxypeptidase II (GCPII) inhibitors.

The NeuroTranslational Program was launched in 2009 staffed with seasoned drug-discovery scientists to work side by side with Johns Hopkins faculty to help translate basic science discoveries into small molecule therapeutics. Under the terms of the agreement, Eisai has granted the Brain Science Institute, or BSI, non-exclusive U.S. rights to use its GCPII technology to generate inhibitor molecules for diseases of the central and peripheral nervous system, including peripheral neuropathy and neurodegeneration, Alzheimer's disease, stroke, and ALS, as well as non-central nervous system diseases.

Genetic Engineering & Biotechnology News


PR Newswire